TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01796106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride varnish & Oral hygiene instruction
Description: Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth oral hygiene instruction and topical fluoridation therapy will be provided. For topical fluoridation Duraphat Fluoride Varnish (Colgate, USA) will be used according to manufactures´ instructions.
Study: NCT01960764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Treatment with Dial liquid antibacterial soap
Description: This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT01566981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computerised support to the Diabetes type II patients
Description: The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
Study: NCT02177942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test beverage powder (High Proteins and added micronutrients)
Description: High protein and added Micronutrients at recommended dietary allowance levels

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control beverage powder (Low protein and no added micronutrients)
Description: Low protein and no added micronutrients
Study: NCT02847000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine
Description: Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested \~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests.
Study: NCT02670187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5300
Study: NCT00886587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F# 11054-010
Description: Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
Study: NCT02814890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-assisted Pneumonectomy
Description: Video-assisted Pneumonectomy under general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-assisted Pneumonectomy
Description: Video-assisted Pneumonectomy under general anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block
Description: The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
Study: NCT02698033

Intervention type: DRUG
Intervention: Peanut flour
Description: A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
Study: NCT00886587

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: F# 10495-053
Description: Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
Study: NCT02783261

Intervention type: OTHER
Intervention: CT volumetric measurement after Y90 radioembolization
Description: Liver volume will be measure at 3 time points. All patients will undergo CT volumetry at baseline, 4-6 weeks and 8-12 weeks after SIRT. The images are then measured using a commercially available 3D software (Vital's Vitrea Advanced CT Liver Oncology package) and manually corrected, reviewed and resected by a single senior radiologist to ensure consistency in following the same anatomical landmarks.
Study: NCT04368091

Intervention type: DEVICE
Intervention: Xtreme Touch - Neo sirolimus coated PTA balloon catheter
Description: The Xtreme Touch (Magic Touch PTA) - Neo Sirolimus PTA Balloon Catheter is the world's first sirolimus coated PTA balloon. The purpose of the X-TOSI all-comers registry is to collect short and long-term clinical performance data on the Xtreme Touch (Magic Touch PTA) -Neo sirolimus PTA balloon catheter in the treatment of atherosclerotic disease in the infrainguinal arteries in an all-comers patient population in real world daily clinical practice.
Study: NCT01090934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Resolution EEG
Description: High Resolution EEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stereo-electroencephalography
Description: SEEG
Study: NCT03884192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Sintilimab
Description: Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.
Study: NCT02698033

Intervention type: OTHER
Intervention: Toasted oat flour
Description: A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
Study: NCT00431483

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: pharmaceutical consulting
Description: to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
Study: NCT00861432

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: additive homeopathic treatment
Description: These patients receive additive homeopathic treatment
Study: NCT03626922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle until maximum of 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle until maximum of 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
Study: NCT04886466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core stability in a sitting position and while walking in one place
Description: The intervention consisted of checking how the active tension of the multisection and transverse abdominal muscles affects the pattern of the trunk movement (in the sitting position) and the work of the lower limbs and the speed of movement while walking in a place.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core stability in a sitting position and while walking in one place
Description: The intervention consisted of checking how the active tension of the multisection and transverse abdominal muscles affects the pattern of the trunk movement (in the sitting position) and the work of the lower limbs and the speed of movement while walking in a place.
Study: NCT02522598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 injections
Description: Colorless, transparent liquid in water for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection
Study: NCT02622698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prostat AWC
Description: Prostat AWC- patients received protein supplementation after surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- Patients did not take any protein supplementation after surgery
Study: NCT01044446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin
Description: one exchange daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucose-based peritoneal dialysate
Description: original exchange frequency
Study: NCT03649191

Intervention type: OTHER
Group type: OTHER
Intervention: The BABEL Approach to Advance Care Planning in Nursing Homes
Description: In intervention nursing homes, eligible residents will: (i) receive The BABEL Approach to Advance Care Planning (ACP), (ii) after these ACP discussions occur, the resident's primary care physician will be notified of the residents' ACP wishes, (iii) a brightly colored document will be placed in a standard location of the NH chart that identifies the resident's ACP wishes, (iv) paramedics will be educated to know about these sheets and where to find them, and that they should be taken with any resident transferred to another care setting.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group Advance Care Planning
Description: Eligible residents in each control nursing homes will receive the prevalent approach to Advance Care Planning in that nursing home. No elements of The BABEL Approach to Advance Care Planning will be introduced in the control homes.
Study: NCT01115036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.
Study: NCT01281657

Intervention type: DRUG
Intervention: fingolimod
Study: NCT01409837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug DY1 while group B was started on the coded drug DZ2. Both DY1 and DZ2 were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug DZ2 while group B changed to drug DY1. There was no intervening washout period. The codes were concealed until after the data analysis.
Study: NCT01540500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 5.66 mg dose on Day 1 and Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: 50 mg Dose on Days 2-8
Study: NCT01703546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAGB & LGCP
Description: All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band \& Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
Study: NCT02082990

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face Brief Intervention
Description: One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
Study: NCT01889615

Intervention type: OTHER
Intervention: PET/CT(3hours]
Description: Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
Study: NCT02082990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Brief Intervention
Description: Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
Study: NCT05405244

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 2 capsules, orally administered once

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 2 capsules, orally administered once

Intervention type: DRUG
Group type: OTHER
Intervention: Bromocriptine-QR
Description: 1.6mg (2 0.8mg capsules), orally administered once

Intervention type: DRUG
Group type: OTHER
Intervention: Bromocriptine-QR
Description: 1.6mg (2 0.8mg capsules), orally administered once
Study: NCT01849107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma citrulline
Study: NCT04388137

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study: NCT03605732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self help sleep hygiene intervention application
Description: This intervention lasts for six weeks. The intervention is App-based and mainly consists of the most potent CBT techniques as well Health action process approach. Weekly feedback is provided by health psychologists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients education
Description: Participants in the PE group will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
Study: NCT00055991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexarotene
Description: This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bexarotene
Description: This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
Study: NCT01241747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: 3 times per week for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Resistance training 3 times per week for 3 months
Study: NCT03626922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle until maximum of 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin-Dose level1: 85 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~Dose level 2: 120 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~The MTD dose of oxaliplatin in the study combination of Cohort 2 will be the recommended Phase II dose (RP2D) for the cohort expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone-4 mg by mouth twice daily on: the day before, the day of, and the day after each dose of pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone-4 mg by mouth twice daily on: the day before, the day of, and the day after each dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic Acid-400 micrograms by mouth daily starting 5 days prior to first dose of pemetrexed and continue daily to include 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic Acid-400 micrograms by mouth daily starting 5 days prior to first dose of pemetrexed and continue daily to include 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B-12
Description: 1000 micrograms administered intramuscularly 7 days prior to the first dose of pemetrexed, every 9 weeks, and should continue until 3 weeks after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B-12
Description: 1000 micrograms administered intramuscularly 7 days prior to the first dose of pemetrexed, every 9 weeks, and should continue until 3 weeks after the last dose of pemetrexed.
Study: NCT02505009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Both case and control will receive 300 mg Tenofovir for at least 3 years
Study: NCT03224403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test acetaminophen
Description: single dose of 2 Test acetaminophen 500 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial acetaminophen
Description: single dose of 2 acetaminophen 500 mg caplets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial ibuprofen
Description: Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo caplets
Study: NCT03165123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Azithromycin tablet
Description: Oral azithromycin tablet will be given one hour before induction of anaesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dexamethasone
Description: 5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous dexamethasone
Description: 5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
Study: NCT03100539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapist treated massage
Description: Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care ally assisted massage
Description: CA-M consisted of in-person training for veteran/care-ally dyads to learn a standardized 30-minue massage routine, instructional DVD, and printed treatment manual. Participants were to complete three care ally-assisted massage sessions weekly for 12-weeks.
Study: NCT00593853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride
Description: Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
Study: NCT04656795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117
Study: NCT05340634

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Metionac
Description: Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metionac
Description: Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptive
Description: Drospirenone 4 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive
Description: Drospirenone 4 mg once a day
Study: NCT02683070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral pudendal nerve block
Description: Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tramadol
Description: Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
Study: NCT00642174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
Study: NCT01730339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-06473871
Description: Single dose administered by injection four different times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-06473871
Description: Single dose administered by injection three different times